NCT04975256: Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)

NCT04975256
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: KRAS
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have a tumor with the KRAS G12C mutation
Exclusions: 
https://ClinicalTrials.gov/show/NCT04975256

Comments are closed.

Up ↑